M Dytoc1, P T Ting, J Man, D Sawyer, L Fiorillo. 1. Faculty of Medicine, University of Calgary, Calgary, Alberta T6G 2G3, Canada. research@mdskinhealth.com
Abstract
BACKGROUND: Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta. OBJECTIVE: Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea. METHODS: Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months. RESULTS: The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness. CONCLUSION: This is the first case series describing the successful application of imiquimod in the management of morphoea.
BACKGROUND: Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta. OBJECTIVE: Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea. METHODS:Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months. RESULTS: The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness. CONCLUSION: This is the first case series describing the successful application of imiquimod in the management of morphoea.
Authors: Tae Woo Noh; Sang Hoon Park; Yoo Seok Kang; Un Ha Lee; Hyun Su Park; Sang Jai Jang Journal: Ann Dermatol Date: 2011-05-27 Impact factor: 1.444
Authors: Suzanne C Li; Kathryn S Torok; Elena Pope; Fatma Dedeoglu; Sandy Hong; Heidi T Jacobe; C Egla Rabinovich; Ronald M Laxer; Gloria C Higgins; Polly J Ferguson; Andrew Lasky; Kevin Baszis; Mara Becker; Sarah Campillo; Victoria Cartwright; Michael Cidon; Christi J Inman; Rita Jerath; Kathleen M O'Neil; Sheetal Vora; Andrew Zeft; Carol A Wallace; Norman T Ilowite; Robert C Fuhlbrigge Journal: Arthritis Care Res (Hoboken) Date: 2012-08 Impact factor: 4.794
Authors: Tamás Constantin; Ivan Foeldvari; Clare E Pain; Annamária Pálinkás; Peter Höger; Monika Moll; Dana Nemkova; Lisa Weibel; Melinda Laczkovszki; Philip Clements; Kathryn S Torok Journal: Eur J Pediatr Date: 2018-05-04 Impact factor: 3.183
Authors: Julia V de Albuquerque; Brenda Ng Andriolo; Monica Ra Vasconcellos; Vinicius T Civile; Anne Lyddiatt; Virginia Fm Trevisani Journal: Cochrane Database Syst Rev Date: 2019-07-16